Natural Products in the Metabolic and Endocrine Modulation of Polycystic Ovary Syndrome: Current Perspectives
Nutrients · 2026
DOI: 10.3390/nu18060964 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, 2026. Verfasst von Siqi Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Interdisciplinary Integrative Medicine Research, School of Medicine, Nantong University, Nantong 226001, China. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Biological Products. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 271 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xinjiang Special Program for Supporting Talent in Critical Fields, National Natural Science Foundation of China, Qinghai Province Key Research and Development and Transformation Plan.
Abstract (Originalsprache)
Polycystic ovary syndrome (PCOS) is a prevalent endocrine and metabolic disorder, primarily characterized by reproductive dysfunction, insulin resistance (IR), and long-term metabolic complications. Current first-line pharmacological treatments, including oral contraceptives, anti-androgens, and insulin sensitizers, can alleviate clinical symptoms but often fail to fully address the underlying pathophysiology, and their long-term use is frequently limited by adverse effects. Natural products, owing to their multi-target regulatory properties and favorable safety profiles, have emerged a promising adjuvant therapeutic strategy. This review systematically summarizes how natural products exert beneficial effects through mechanisms such as improving metabolic homeostasis by enhancing insulin sensitivity and mitigating oxidative stress and chronic inflammation; restoring endocrine balance by modulating the hypothalamic–pituitary–gonadal axis to reduce hyperandrogenemia and promote ovulation; and utilizing emerging pathways including regulating gut microbiota homeostasis and epigenetic modifications as a novel avenue for PCOS drug development. Preclinical and clinical evidence collectively indicates that these agents hold significant translational potential to ameliorate metabolic disturbances and improve reproductive outcomes, providing a scientific foundation for future integrated intervention strategies in PCOS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Interdisciplinary Integrative Medicine Research, School of Medicine, Nantong University, Nantong 226001, China.
- Department of Pharmaceutical Botany, School of Pharmacy, Naval Medical University, Shanghai 200433, China.
ORCID-Profile: Siqi Liu, Rui Wang, Chuanjing Shi, Xi Wang, Aifen Liu, Lei Zhang
Förderung
- Xinjiang Special Program for Supporting Talent in Critical Fields
- National Natural Science Foundation of China
- Qinghai Province Key Research and Development and Transformation Plan
- The Open Project of Qinghai Key Laboratory of Qinghai-Tibet Plateau Biological Resources, and Postgraduate Research and Practice Innovation Program of Jiangsu…
Zitieren
APA
Liu, S., Wang, R., Yu, W., Shi, C., Wang, X., Liu, A., & Zhang, L. (2026). Natural Products in the Metabolic and Endocrine Modulation of Polycystic Ovary Syndrome: Current Perspectives. Nutrients. https://doi.org/10.3390/nu18060964
Vancouver
Liu S, Wang R, Yu W, Shi C, Wang X, Liu A, et al. Natural Products in the Metabolic and Endocrine Modulation of Polycystic Ovary Syndrome: Current Perspectives. Nutrients. 2026. doi:10.3390/nu18060964
BibTeX
@article{Liu2026,
author = {Liu, Siqi and Wang, Rui and Yu, Weili and Shi, Chuanjing and Wang, Xi and Liu, Aifen and Zhang, Lei},
title = {Natural Products in the Metabolic and Endocrine Modulation of Polycystic Ovary Syndrome: Current Perspectives},
journal = {Nutrients},
year = {2026},
doi = {10.3390/nu18060964}
}
EUVIMED